Powerful efficacy* observed

*Superior progression-free survival (PFS) in combination treatment was seen in clinical trials (KRd vs Rd and Kd vs Vd). 'See Results' above.
†ENDEAVOR = RandomizEd, OpeN label, Phase 3 Study of Carfilzomib Plus DExamethAsone Vs Bortezomib Plus DexamethasOne in Patients With Relapsed Multiple Myeloma.
‡ASPIRE = CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma.
Kd = KYPROLIS and dexamethasone; KRd = KYPROLIS, lenalidomide, and dexamethasone; Rd = lenalidomide and dexamethasone; Vd = bortezomib and dexamethasone.

KYPROLIS doublet (Kd) and KYPROLIS triplet (KRd) regimens in relapsed multiple myeloma

Kd 56 mg/m2 therapeutic dose
KRd 27 mg/m2 therapeutic dose
See KYPROLIS dosing
See safety profile

Safety profile of KYPROLIS doublet (Kd) and KYPROLIS triplet (KRd) regimens and treatment duration


Ready to connect to patient support

Onyx Pharmaceuticals 360®

Important Safety Information

Cardiac Toxicities

  • New onset or worsening of pre-existing cardiac failure (e.g., congestive heart failure, pulmonary edema, decreased ejection fraction), restrictive cardiomyopathy, myocardial ischemia, and myocardial infarction including fatalities have occurred following administration of KYPROLIS. Some events occurred in patients with normal baseline ventricular function. Death due to cardiac arrest has occurred within one day of KYPROLIS administration.
  • Monitor patients for clinical signs or symptoms of cardiac failure or cardiac ischemia. Evaluate promptly if cardiac toxicity is suspected. Withhold KYPROLIS for Grade 3 or 4 cardiac adverse events until recovery, and consider whether to restart KYPROLIS at 1 dose level reduction based on a benefit/risk assessment.
  • While adequate hydration is required prior to each dose in Cycle 1, monitor all patients for evidence of volume overload, especially patients at risk for cardiac failure. Adjust total fluid intake as clinically appropriate in patients with baseline cardiac failure or who are at risk for cardiac failure.
  • Patients ≥ 75 years, the risk of cardiac failure is increased. Patients with New York Heart Association Class III and IV heart failure, recent myocardial infarction, conduction abnormalities, angina, or arrhythmias may be at greater risk for cardiac complications and should have a comprehensive medical assessment (including blood pressure and fluid management) prior to starting treatment with KYPROLIS and remain under close follow-up.

Acute Renal Failure

Tumor Lysis Syndrome

Pulmonary Toxicity

Pulmonary Hypertension



Venous Thrombosis

Infusion Reactions



Hepatic Toxicity and Hepatic Failure

Thrombotic Microangiopathy

Posterior Reversible Encephalopathy Syndrome (PRES)

Embryo-fetal Toxicity

Adverse reactions

Please see full Prescribing Information.